Staidson Beijing Biopharma Strategic Asset Allocation Index
Staidson Beijing Biopharma strategic asset allocation index. Staidson Beijing Biopharma (300204) has a Strategic Asset Allocation Index of 22.4% as of June 2023. Strategic assets (PP&E of CN¥273.52 Million plus long-term investments of CN¥-) total CN¥273.52 Million, measured against net assets of CN¥1.22 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check tangible equity quality of Staidson Beijing Biopharma to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Staidson Beijing Biopharma (2008–2022)
Strategic asset allocation index of Staidson Beijing Biopharma from 2008 to 2022. This chart shows how Staidson Beijing Biopharma's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 22.4%, representing strategic assets of CN¥273.52 Million against net assets of CN¥1.22 Billion CNY.
Staidson Beijing Biopharma Strategic Asset Allocation Index by Year (2008–2022)
Staidson Beijing Biopharma strategic asset allocation index by year from 2008 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Staidson Beijing Biopharma from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Staidson Beijing Biopharma.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 21.5% | CN¥290.58 Million | CN¥290.58 Million | CN¥- | CN¥1.35 Billion | ▲ +1.3 pp |
| 2021 | 20.1% | CN¥312.43 Million | CN¥312.43 Million | CN¥- | CN¥1.55 Billion | ▲ +1.6 pp |
| 2020 | 18.6% | CN¥295.17 Million | CN¥295.17 Million | CN¥- | CN¥1.59 Billion | ▼ -24.1 pp |
| 2019 | 42.7% | CN¥697.95 Million | CN¥317.18 Million | CN¥380.77 Million | CN¥1.64 Billion | ▼ -1.7 pp |
| 2018 | 44.4% | CN¥1.09 Billion | CN¥298.68 Million | CN¥792.60 Million | CN¥2.46 Billion | ▲ +13.5 pp |
| 2017 | 30.9% | CN¥683.18 Million | CN¥247.30 Million | CN¥435.88 Million | CN¥2.21 Billion | ▲ +10.3 pp |
| 2016 | 20.7% | CN¥396.39 Million | CN¥243.41 Million | CN¥152.98 Million | CN¥1.92 Billion | ▲ +5.9 pp |
| 2015 | 14.8% | CN¥248.43 Million | CN¥240.24 Million | CN¥8.19 Million | CN¥1.68 Billion | ▼ -1.0 pp |
| 2014 | 15.8% | CN¥238.78 Million | CN¥238.78 Million | CN¥- | CN¥1.51 Billion | ▼ -3.9 pp |
| 2013 | 19.7% | CN¥258.46 Million | CN¥258.46 Million | CN¥- | CN¥1.31 Billion | ▲ +0.0 pp |
| 2012 | 19.6% | CN¥243.45 Million | CN¥243.45 Million | CN¥- | CN¥1.24 Billion | ▲ +0.6 pp |
| 2011 | 19.1% | CN¥210.08 Million | CN¥210.08 Million | CN¥- | CN¥1.10 Billion | ▼ -61.3 pp |
| 2010 | 80.4% | CN¥133.62 Million | CN¥133.62 Million | CN¥- | CN¥166.23 Million | ▲ +51.8 pp |
| 2009 | 28.6% | CN¥34.24 Million | CN¥34.24 Million | CN¥- | CN¥119.72 Million | ▼ -8.6 pp |
| 2008 | 37.2% | CN¥23.35 Million | CN¥23.35 Million | CN¥- | CN¥62.82 Million | — |